O	0	8	Efficacy
O	9	11	of
B-intervention	12	21	tamoxifen
I-intervention	22	31	following
I-intervention	32	43	anastrozole
O	44	45	(
O	45	46	'
O	46	54	Arimidex
O	54	55	'
O	55	56	)
O	57	65	compared
O	66	70	with
B-control	71	82	anastrozole
I-control	83	92	following
I-control	93	102	tamoxifen
O	103	105	as
O	106	111	first
O	111	112	-
O	112	116	line
O	117	126	treatment
O	127	130	for
O	131	139	advanced
O	140	146	breast
O	147	153	cancer
O	154	156	in
O	157	171	postmenopausal
O	172	177	women
O	177	178	.

O	179	190	Anastrozole
O	191	192	(
O	192	193	'
O	193	201	Arimidex
O	201	202	'
O	202	203	)
O	204	206	is
O	207	216	indicated
O	217	220	for
O	221	224	the
O	225	234	treatment
O	235	237	of
O	238	246	advanced
O	247	253	breast
O	254	260	cancer
O	261	263	in
O	264	278	postmenopausal
O	279	284	women
O	284	285	.

O	286	294	Combined
O	295	303	analysis
O	304	306	of
O	307	310	two
O	311	324	international
O	325	335	randomised
O	335	336	,
O	337	343	double
O	343	344	-
O	344	349	blind
O	350	356	trials
O	357	358	(
O	358	359	n
O	359	360	=
B-total-participants	360	364	1021
O	364	365	)
O	366	372	showed
O	373	377	that
O	378	380	in
B-eligibility	381	389	patients
I-eligibility	390	394	with
I-eligibility	395	402	hormone
I-eligibility	403	411	receptor
I-eligibility	411	412	-
I-eligibility	412	420	positive
I-eligibility	421	428	tumours
O	428	429	,
O	430	435	first
O	435	436	-
O	436	440	line
O	441	450	treatment
O	451	455	with
O	456	467	anastrozole
O	468	481	significantly
O	482	491	prolonged
O	492	495	the
B-outcome	496	500	time
I-outcome	501	503	to
I-outcome	504	515	progression
I-outcome	516	517	(
I-outcome	517	520	TTP
I-outcome	520	521	)
O	522	530	compared
O	531	535	with
O	536	545	tamoxifen
O	546	547	(
O	547	553	median
O	554	557	TTP
O	557	558	:
B-iv-cont-median	559	561	10
I-iv-cont-median	561	562	.
I-iv-cont-median	562	563	7
O	564	570	versus
B-cv-cont-median	571	572	6
I-cv-cont-median	572	573	.
I-cv-cont-median	573	574	4
I-cv-cont-median	575	581	months
O	581	582	,
O	583	595	respectively
O	595	596	;
O	597	598	P
O	598	599	=
O	599	600	0
O	600	601	.
O	601	604	022
O	604	605	)
O	605	606	.

O	607	613	Second
O	613	614	-
O	614	618	line
O	619	628	tamoxifen
O	629	638	following
O	639	650	anastrozole
O	650	651	,
O	652	654	or
O	655	659	vice
O	660	665	versa
O	665	666	,
O	667	669	in
O	670	674	this
O	675	680	trial
O	681	691	population
O	692	695	was
O	696	705	unblinded
O	705	706	.

O	707	710	The
O	711	721	treatments
O	722	726	were
O	727	734	crossed
O	735	739	over
O	740	743	and
O	744	748	then
O	749	757	efficacy
O	758	761	was
O	762	770	assessed
O	771	776	using
O	777	778	a
O	779	792	questionnaire
O	792	793	.

O	794	796	Of
B-intervention-participants	797	800	511
O	801	809	patients
O	810	820	randomised
O	821	823	to
O	824	835	anastrozole
O	835	836	,
B-iv-bin-abs	837	840	137
O	841	842	(
B-iv-bin-percent	842	844	26
I-iv-bin-percent	844	845	.
I-iv-bin-percent	845	846	8
I-iv-bin-percent	846	847	%
O	847	848	)
B-outcome	849	857	received
I-outcome	858	864	second
I-outcome	864	865	-
I-outcome	865	869	line
I-outcome	870	879	tamoxifen
O	879	880	.

O	881	894	Questionnaire
O	895	899	data
O	900	904	were
O	905	914	available
O	915	918	for
B-total-participants	919	922	119
O	923	931	patients
O	931	932	;
B-iv-bin-abs	933	935	58
O	936	937	(
B-iv-bin-percent	937	939	48
I-iv-bin-percent	939	940	.
I-iv-bin-percent	940	941	7
I-iv-bin-percent	941	942	%
O	942	943	)
B-outcome	944	950	gained
I-outcome	951	959	clinical
I-outcome	960	967	benefit
O	968	969	(
O	969	971	CB
O	971	972	=
O	972	980	complete
O	980	981	+
O	981	988	partial
O	989	997	response
O	998	999	(
O	999	1001	CR
O	1001	1002	+
O	1002	1004	PR
O	1004	1005	)
O	1005	1006	+
O	1006	1007	(
O	1007	1013	stable
O	1014	1021	disease
O	1022	1023	(
O	1023	1025	SD
O	1025	1026	)
O	1027	1028	>
O	1028	1029	/
O	1029	1030	=
O	1030	1032	24
O	1033	1038	weeks
O	1038	1039	)
O	1039	1040	)
O	1040	1041	,
O	1042	1047	while
B-iv-bin-abs	1048	1050	12
O	1051	1052	(
B-iv-bin-percent	1052	1054	10
I-iv-bin-percent	1054	1055	.
I-iv-bin-percent	1055	1056	1
I-iv-bin-percent	1056	1057	%
O	1057	1058	)
O	1059	1062	had
O	1063	1065	an
B-outcome	1066	1075	objective
I-outcome	1076	1084	response
O	1085	1086	(
O	1086	1088	OR
O	1088	1089	=
O	1089	1091	CR
O	1091	1092	+
O	1092	1094	PR
O	1094	1095	)
O	1095	1096	.

O	1097	1099	Of
B-control-participants	1100	1103	510
O	1104	1112	patients
O	1113	1123	randomised
O	1124	1126	to
O	1127	1136	tamoxifen
O	1136	1137	,
B-cv-bin-abs	1138	1141	134
O	1142	1143	(
B-cv-bin-percent	1143	1145	26
I-cv-bin-percent	1145	1146	.
I-cv-bin-percent	1146	1147	3
I-cv-bin-percent	1147	1148	%
O	1148	1149	)
B-outcome	1150	1158	received
I-outcome	1159	1165	second
I-outcome	1165	1166	-
I-outcome	1166	1170	line
I-outcome	1171	1182	anastrozole
O	1182	1183	.

O	1184	1197	Questionnaire
O	1198	1202	data
O	1203	1207	from
O	1208	1210	95
O	1211	1219	patients
O	1220	1226	showed
O	1227	1231	that
B-cv-bin-abs	1232	1234	54
O	1235	1236	(
B-cv-bin-percent	1236	1238	56
I-cv-bin-percent	1238	1239	.
I-cv-bin-percent	1239	1240	8
I-cv-bin-percent	1240	1241	%
O	1241	1242	)
B-outcome	1243	1249	gained
I-outcome	1250	1252	CB
O	1253	1256	and
B-cv-bin-abs	1257	1258	7
O	1259	1261	of
O	1262	1265	the
O	1266	1274	patients
O	1275	1282	gaining
O	1283	1285	CB
O	1286	1287	(
B-cv-bin-percent	1287	1288	7
I-cv-bin-percent	1288	1289	.
I-cv-bin-percent	1289	1290	4
I-cv-bin-percent	1290	1291	%
O	1291	1292	)
O	1293	1296	had
O	1297	1299	an
B-outcome	1300	1302	OR
O	1302	1303	.

O	1304	1312	Previous
O	1313	1320	studies
O	1321	1327	showed
O	1328	1339	anastrozole
O	1340	1342	is
O	1343	1352	effective
O	1353	1358	after
O	1359	1364	first
O	1364	1365	-
O	1365	1369	line
O	1370	1379	tamoxifen
O	1379	1380	.

O	1381	1386	These
O	1387	1391	data
O	1392	1396	show
O	1397	1401	that
O	1402	1405	the
O	1406	1416	sequential
O	1417	1431	administration
O	1432	1434	of
O	1435	1440	first
O	1440	1441	-
O	1441	1445	line
O	1446	1457	anastrozole
O	1458	1466	followed
O	1467	1469	by
O	1470	1479	tamoxifen
O	1480	1488	provides
O	1489	1498	effective
O	1499	1502	use
O	1503	1505	of
O	1506	1511	these
O	1512	1517	drugs
O	1518	1520	in
O	1521	1524	the
O	1525	1534	treatment
O	1535	1537	of
O	1538	1552	postmenopausal
O	1553	1558	women
O	1559	1563	with
O	1564	1572	advanced
O	1573	1579	breast
O	1580	1586	cancer
O	1586	1587	.
